The Ongoing Management of Hyperkalaemia in Chronic Kidney Disease Patients: Cases for Clinical Decisions - European Medical Journal

The Ongoing Management of Hyperkalaemia in Chronic Kidney Disease Patients: Cases for Clinical Decisions

Download PDF
David C. Wheeler1
Francesco Locatelli,2 Adrian Covic,3 David C. Wheeler1

David C. Wheeler received honoraria from ZS Pharma for consultancy and speaking commitments. Francesco Locatelli was a member of an advisory board of ZS Pharma. Adrian Covic is a speaker and consultant for ZS Pharma.


Writing assistance was provided by Dr Ana Rodríguez de Ledesma, apothecom scopemedical ltd.


The symposium was organised by Medavera, Inc. and supported by an educational grant from ZS Pharma. Authors received honoraria for preparation and delivery of their presentations. The views and opinions expressed are those of the authors and not necessarily of Medavera, Inc. or ZS Pharma.

EMJ Nephrol. ;3[1]:46-55. DOI/10.33590/emjnephrol/10314961.
ERA-EDTA Congress 2015, European Dialysis and Transplant Association, European Renal Association.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

This educational symposium provided an insight into the most current clinical evidence of the efficacy and safety of renin—angiotensin—aldosterone system inhibitors (RAASis) for patients with chronic kidney disease (CKD). The programme provided an opportunity to discuss ways to optimise and maintain RAASis in this population by introducing CKD patient cases and the dilemmas of their clinical presentation, and novel treatment options, including benefits, harms, and potential consequences.

Prof David C. Wheeler introduced the debate about the use of RAASis and the associated risk of hyperkalaemia in CKD patients. Prof Francesco Locatelli discussed the management of blood pressure (BP) in CKD and reviewed the most current guidelines for the prevention of hyperkalaemia in this population. Prof Adrian Covic presented the controversies around the use of RAASis in specific group populations. Survival, cardiovascular events (CVEs), and progression of CKD were the main points of his presentation. Finally, Prof David C. Wheeler discussed the latest research on novel therapies for the management of hyperkalaemia.

Please view the full content in the pdf above.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now